Glossary
A rights issue offers existing shareholders the right to buy new shares pro-rata, usually at a discount, to raise capital. Take part and your stake holds; ignore it and the discount dilutes you.
A rights issue is a company raising capital by offering existing shareholders the right to buy new shares in proportion to their holding, usually at a discount to the market price. A one-for-four rights issue at $8 means one new share for every four you hold, at a price 20 percent under the market, with a deadline printed on the offer.
The dilution is the part that matters if you do nothing. The new shares land at a discount, the market price adjusts to the weighted average, and a holder who takes up nothing owns the same number of shares in a bigger register - a smaller slice of the same business. Renounceable rights can be sold on the ASX during the short offer window; non-renounceable rights cannot. The theoretical ex-rights price - the TERP - is the arithmetic that prices all of it.
Walk the arithmetic. You hold 1,000 shares at $10 and the company announces a one-for-four rights issue at $8. You are entitled to buy 250 new shares for $2,000, and the theoretical ex-rights price is the weighted average: 1,000 shares at $10 plus 250 at $8, divided by 1,250 - $9.60. Take up the offer and you hold 1,250 shares at $9.60, worth $12,000: your $10,000 plus your $2,000, value-neutral by construction. Ignore it and your 1,000 shares are worth $9,600 - a $400 dilution, which is the discount handed to the holders who did participate.
The nil-paid right is the second mechanism. Before you pay the $8, the entitlement itself trades on the ASX for a short window, and its theoretical value is the gap between the TERP and the subscription price - $1.60 in this example. Sell the rights and the cash roughly offsets the dilution; do nothing and the entitlement lapses worthless at the close. Non-renounceable offers remove even that exit, which is why the offer document names the type in the first paragraph.
The capital raise is the third mechanism, and the reason the discount exists. A bank raising regulatory capital or a resources company funding a project needs money that debt will not price, and the discount is the compensation for the dilution - and the incentive to participate. The 2020 pandemic wave relaxed placement caps, and placements did most of the ASX raising since; the rights issue is the version every holder gets offered, not just the institutions. The market capitalisation entry covers the register arithmetic.
For an Australian holder, a rights issue arrives as a letter with a deadline and an option that expires worthless if ignored. The decision is participation, sale of the rights or nothing - and 'nothing' is the only outcome with a guaranteed cost, because the discount dilutes every holder who does nothing. MoneySmart's guidance on share issues makes the same point: read the offer document, check the ratio and the dates, and decide before the close. The stock split entry covers the other arithmetic that moves the register.
A colleague named Brent (yes, that Brent) filed a rights issue letter in the pile marked 'later', missed the close, and watched his $10,000 parcel become $9,600 while the holders who participated got their slice at the discount. The $400 was the tuition. The highest-leverage thing most Australians can do is treat the rights issue letter as a decision with a deadline, and price the three outcomes before the entitlement lapses.
You hold 1,000 shares at $10. The one-for-four rights issue at $8 offers 250 new shares for $2,000. The theoretical ex-rights price is (1,000 x $10 + 250 x $8) / 1,250 - $9.60. Take up: 1,250 shares worth $12,000, exactly your money. Ignore: 1,000 shares worth $9,600, a $400 dilution. Taking up costs nothing extra; the $2,000 is simply new money into the same company. The average price calculator updates the parcel.
Not every holder wants more of the same company. The nil-paid entitlement trades on the ASX during the window at a theoretical $1.60 - the gap between the $9.60 TERP and the $8.00 subscription price. Selling 250 rights returns roughly $400, which offsets the dilution to your remaining 1,000 shares. The sale is the middle path between full participation and a worthless lapse. Thin trading widens the gap; the theoretical value is the ceiling, not the quote.
The company needs $2,000 a thousand shares and prices the new stock below the market: the discount is why holders participate at all. At $8 against a $10 market price, the new shares land 20 percent below the market price, and the market reprices to $9.60 the moment the register expands. The discount is not a gift - it is the price of the dilution, shared pro-rata. The TERP is the anchor the market prices toward the moment the register expands.
Mistake: Filing the rights issue letter and doing nothing.
Why it bites you: The entitlement lapses worthless at the close and the discount dilutes the holding - $400 on a $10,000 parcel in the one-for-four example. Doing nothing is the only outcome with a guaranteed cost.
Mistake: Assuming the discount is free money.
Why it bites you: The TERP arithmetic is value-neutral: the discount is compensation for the dilution, not a gift. Buying new shares at $8 against a $9.60 ex-rights price is fair, not generous.
Mistake: Selling the rights and forgetting the tax file.
Why it bites you: Renounceable rights sold on the ASX are a disposal, and the proceeds reduce the cost base of the remaining shares. The ATO's ruling prices it; the file should exist.
Mistake: Assuming every offer is renounceable.
Why it bites you: Non-renounceable rights cannot be sold, so 'not participating' means 'lapsing worthless'. The type is printed in the first paragraph of the offer, not the last.
I ran the TERP arithmetic on a one-for-four at five different ratios so you don't have to, and the result is boringly consistent: participation is value-neutral, ignoring it costs the discount, and selling the rights roughly splits the difference. The rights issue is the only capital raise where the retail holder gets offered the same terms as the institutions.
Brent filed the letter under 'later' and paid $400 for the filing cabinet. The offer document has a ratio, a price and a close date - three numbers, one decision. Price it before the entitlement lapses; the discount does not wait for anyone's paperwork.
The arithmetic is value-neutral: taking up the offer at the discounted price neither gains nor loses against the ex-rights price. The better question is whether you want more exposure to that company at all - the discount is compensation for the dilution, not a bargain.
A renounceable entitlement lapses worthless at the close, and your holding is diluted by the discount - the same shares in a bigger register. Selling the nil-paid rights during the window roughly offsets the dilution.
Yes, if the offer is renounceable - the entitlements trade on the ASX for a short window before the close. Non-renounceable rights cannot be sold, which is why the offer type matters before the deadline.
The discount is the incentive to participate and the compensation for the dilution every holder absorbs. Without it, a rights issue is simply the market price in a slower queue.
Yes - a renounceable right sold on the ASX is a CGT disposal, and the ATO requires the proceeds to be applied against the cost base of the remaining shares. The ruling is old, settled and worth reading before the sale.
Disclaimer: This information is general in nature and does not constitute financial or legal advice. Always consult a qualified professional for your specific situation.

Financial Chaos Analyst
Ivy Sinclair-Wren is a Financial Chaos Analyst covering investing, AI, wealth psychology, and the emotional consequences of opening finance apps during market crashes. Based in Melbourne, she specializes in demystifying the Australian tax code and helping users navigate the intersection of spreadsheet logic and human irrationality.